AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35588372 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of renal replacement therapy (RRT)
Number of subjects: 10000
Study 35588372 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality during ICU and hospital stay
Number of subjects: 10000
Study 35588372 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of ICU and hospital stay
Number of subjects: 10000
Study 35588372 — intervention group
Group type: EXPERIMENTAL
Intervention: Major adverse kidney events (persistent renal dysfunction, RRT, and mortality) at day 90
Number of subjects: 10000
Study 35588372 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary biomarkers for early detection of AKI
Number of subjects: 10000
Study 35588692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W for 35 cycles (2 years)
Number of subjects: 351
Study 35588734 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α intervention
Number of subjects: 0
Study 35588734 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35588752 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazemetostat 800 mg once on day 1 and then twice daily from day 2 onwards (part 1); Tazemetostat 800 mg twice daily starting on day 1 of cycle 1 (part 2)
Number of subjects: 74
Study 35589029 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral carotid artery stenting (TF-CAS)
Number of subjects: 376
Study 35589029 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 376
Study 35589078 — intervention group
Group type: EXPERIMENTAL
Intervention: Port Delivery System with ranibizumab (PDS)
Number of subjects: 0
Study 35589164 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous statin therapy
Number of subjects: 14542
Study 35589172 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Impedance (LI) drop during pulmonary vein isolation (PVI)
Number of subjects: 58
Study 35589172 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal LI drops identified by left atrial region
Number of subjects: 58
Study 35589172 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting LI before radiofrequency (RF) application
Number of subjects: 58
Study 35589172 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Impedance (LI) drop
Number of subjects: 58
Study 35589172 — intervention group
Group type: EXPERIMENTAL
Intervention: Preablation starting LI
Number of subjects: 58
Study 35589234 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FFR/low CFR
Number of subjects: 2143
Study 35589234 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FFR/normal CFR
Number of subjects: 2143
Study 35589234 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal FFR/low CFR
Number of subjects: 2143
Study 35589234 — intervention group
Group type: COMPARATOR
Intervention: Normal FFR/normal CFR
Number of subjects: 2143
Study 35589234 — intervention group
Group type: COMPARATOR
Intervention: Revascularized vessels
Number of subjects: 2143
Study 35589352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine dual antiretroviral therapy
Number of subjects: 0
Study 35589352 — intervention group
Group type: COMPARATOR
Intervention: Other dual-drug and three-drug combinations
Number of subjects: 0
Study 35589363 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 712
Study 35589542 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 COVID-19 vaccine, 2 doses
Number of subjects: 150
Study 35589542 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated patients
Number of subjects: 150
Study 35589711 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisense oligonucleotide (ASO) targeting the aberrant C9ORF72 transcript
Number of subjects: 0
Study 35589711 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 35589962 — intervention group
Group type: EXPERIMENTAL
Intervention: In-utero co-exposure to Hg, Pb, and Cd
Number of subjects: 1442
Study 35589962 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate maternal micronutrients (selenium and folate)
Number of subjects: 1442
Study 35589975 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 critical care professionals
Number of subjects: 1372
Study 35589975 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients or those with doubts about infection
Number of subjects: 1372
Study 35589975 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak incidence moments
Number of subjects: 1372
Study 35590038 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 315
Study 35590143 — intervention group
Group type: EXPERIMENTAL
Intervention: JAK1 inhibitor itacitinib
Number of subjects: 1
Study 35591977 — intervention group
Group type: EXPERIMENTAL
Intervention: IV etoposide 100 mg/m²
Number of subjects: 25
Study 35592378 — intervention group
Group type: COMPARATOR
Intervention: Modest COVID-19 restrictions (June 9 to October 18, 2020)
Number of subjects: 873
Study 35592378 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong COVID-19 restrictions (October 19, 2020, to April 17, 2021)
Number of subjects: 873
Study 35592378 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong COVID-19 restrictions
Number of subjects: 873
Study 35592490 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (10-week treatment)
Number of subjects: 34
Study 35592490 — intervention group
Group type: COMPARATOR
Intervention: Desvenlafaxine (12-week treatment)
Number of subjects: 34
Study 35592513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation ≥1000 IU/day
Number of subjects: 637
Study 35592513 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D supplementation 200 IU/day
Number of subjects: 637
Study 35592513 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved 25(OH)D concentrations ≥40 ng/mL
Number of subjects: 637
Study 35593638 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated devices
Number of subjects: 0
Study 35593638 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35593967 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wireless monitoring of vital signs (peripheral oxygen saturation, heart rate, respiratory rate) and non-invasive blood pressure measured every 30-60 min
Number of subjects: 200
Study 35594123 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg/day, 200 mg/day, 400 mg/day)
Number of subjects: 48
Study 35594123 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum etonogestrel concentrations
Number of subjects: 48
Study 35594464 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncofertility counseling offered at the time of diagnosis
Number of subjects: 0
Study 35595203 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in cardiac damage stage post-AVR
Number of subjects: 1974
Study 35595203 — intervention group
Group type: EXPERIMENTAL
Intervention: No change in cardiac damage stage post-AVR
Number of subjects: 1974
Study 35595203 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening of cardiac damage stage post-AVR
Number of subjects: 1974
Study 35595320 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frequencies of IgA in patients with severe asthma
Number of subjects: 154
Study 35595320 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory B-cells in severe asthma patients
Number of subjects: 154
Study 35595320 — intervention group
Group type: EXPERIMENTAL
Intervention: Immature B-cell populations in severe asthma patients
Number of subjects: 154
Study 35595617 — intervention group
Group type: EXPERIMENTAL
Intervention: SN-5 questionnaire after 4-week treatment
Number of subjects: 116
Study 35595617 — intervention group
Group type: COMPARATOR
Intervention: SN-5 questionnaire
Number of subjects: 116
Study 35595617 — intervention group
Group type: EXPERIMENTAL
Intervention: SN-5 scores
Number of subjects: 116
Study 35595730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton's tyrosine kinase (BTK)
Number of subjects: 0
Study 35596173 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycaemic clamp followed by hypoglycaemic clamp
Number of subjects: 14
Study 35596181 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (60mg, 200mg, 400mg)
Number of subjects: 36
Study 35596592 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral hypoglossal nerve stimulation
Number of subjects: 29
Study 35596679 — intervention group
Group type: EXPERIMENTAL
Intervention: Downregulated pro-inflammatory complement factor D (CFD)
Number of subjects: 28
Study 35596679 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic profiling
Number of subjects: 28
Study 35596679 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory protein CFD and serpin family B member 1
Number of subjects: 28
Study 35596791 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-4621 monotherapy
Number of subjects: 45
Study 35596791 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-4621 plus pembrolizumab
Number of subjects: 45
Study 35596791 — intervention group
Group type: COMPARATOR
Intervention: MK-4621 monotherapy and MK-4621 plus pembrolizumab
Number of subjects: 45
Study 35596885 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with comorbidities
Number of subjects: 2813
Study 35596885 — intervention group
Group type: COMPARATOR
Intervention: Patients without comorbidities
Number of subjects: 2813
Study 35597052 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible objects
Number of subjects: 0
Study 35597052 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluded objects
Number of subjects: 0
Study 35597752 — intervention group
Group type: EXPERIMENTAL
Intervention: LV20.19 CAR T cells
Number of subjects: 15
Study 35597752 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with CD19 or CD20 antigens
Number of subjects: 15
Study 35597904 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib (250-350 mg on D1 and D15)
Number of subjects: 22
Study 35597904 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib monotherapy
Number of subjects: 22
Study 35597904 — intervention group
Group type: EXPERIMENTAL
Intervention: Volasertib with azacitidine
Number of subjects: 22
Study 35597904 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study 35598186 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib/cobimetinib administered via feeding tube
Number of subjects: 2
Study 35598313 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + PWI radio frequency ablation (RFA)
Number of subjects: 24
Study 35598394 — intervention group
Group type: EXPERIMENTAL
Intervention: Apilimod
Number of subjects: 0
Study 35598394 — intervention group
Group type: EXPERIMENTAL
Intervention: Berbamine
Number of subjects: 0
Study 35598394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cepharanthine
Number of subjects: 0
Study 35598394 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-crizotinib
Number of subjects: 0
Study 35598394 — intervention group
Group type: COMPARATOR
Intervention: Delta and Omicron variants
Number of subjects: 0
Study 35598419 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere subthalamic nucleus deep brain stimulation (DBS) for Parkinson's disease
Number of subjects: 0
Study 35598441 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ733 (300 mg daily for 3 days)
Number of subjects: 27
Study 35598441 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ733 (600 mg daily for 3 days)
Number of subjects: 27
Study 35598441 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ733 (75 mg single dose) + cobicistat (150 mg single dose)
Number of subjects: 27
Study 35598441 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ733 (300 mg single dose) + cobicistat (150 mg single dose)
Number of subjects: 27
Study 35598441 — intervention group
Group type: EXPERIMENTAL
Intervention: SJ733 (600 mg single dose) + cobicistat (150 mg single dose)
Number of subjects: 27
Study 35598441 — intervention group
Group type: COMPARATOR
Intervention: SJ733 (600 mg single dose) ± cobicistat
Number of subjects: 27
Study 35598589 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining WAZ > 0
Number of subjects: 178
Study 35598589 — intervention group
Group type: COMPARATOR
Intervention: Stable around WAZ = 0
Number of subjects: 178
Study 35598589 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially recovered
Number of subjects: 178
Study 35598589 — intervention group
Group type: EXPERIMENTAL
Intervention: Never recovered
Number of subjects: 178
Study 35598604 — intervention group
Group type: EXPERIMENTAL
Intervention: BBM-H901 (5 × 10^13 vg/kg)
Number of subjects: 10
Study 35598604 — intervention group
Group type: EXPERIMENTAL
Intervention: BBM-H901
Number of subjects: 10
Study 35598718 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive eating monitoring via wrist-worn device measuring bites, eating duration, and eating rate
Number of subjects: 25
Study 35599187 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide-cisplatin (EP) followed by carboplatin (CARBO)
Number of subjects: 102
Study 35599187 — intervention group
Group type: COMPARATOR
Intervention: Etoposide-cisplatin (EP)
Number of subjects: 102
Study 35599187 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (CARBO)
Number of subjects: 102
Study 35599248 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb
Number of subjects: 20
Study 35599261 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding for 8 weeks
Number of subjects: 22
Study 35599302 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH1-vac
Number of subjects: 48
Study 35599302 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH1-vac + AVE
Number of subjects: 48
Study 35599302 — intervention group
Group type: COMPARATOR
Intervention: AVE only
Number of subjects: 48
Study 35599306 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo PEG-IFN therapy
Number of subjects: 390
Study 35599306 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on PEG-IFN therapy
Number of subjects: 390
Study 35599306 — intervention group
Group type: COMPARATOR
Intervention: Anti-HBc levels
Number of subjects: 390
Study 35599315 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED)
Number of subjects: 211
Study 35599349 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity paradigm (M = 4.11; SD = 0.78)
Number of subjects: 1244
Study 35599349 — intervention group
Group type: COMPARATOR
Intervention: Rest paradigm (M = 2.56; SD = 0.78)
Number of subjects: 1244
Study 35599736 — intervention group
Group type: EXPERIMENTAL
Intervention: CCFES plus cHMC rTMS
Number of subjects: 72
Study 35599736 — intervention group
Group type: EXPERIMENTAL
Intervention: CCFES plus iM1 rTMS
Number of subjects: 72
Study 35599736 — intervention group
Group type: COMPARATOR
Intervention: CCFES plus sham rTMS
Number of subjects: 72
Study 35599977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress symptoms assessment through interviews conducted by child and adolescent psychologists and psychiatrists from day 1 to day 3 post-storm.
Number of subjects: 116
Study 35599977 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 0-5 years
Number of subjects: 116
Study 35599977 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 6-11 years
Number of subjects: 116
Study 35600486 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W plus statin therapy (atorvastatin 20 mg/day or rosuvastatin 10 mg/day)
Number of subjects: 0
Study 35600486 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy
Number of subjects: 0
Study 35601412 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO supplement
Number of subjects: 0
Study 35601412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35602004 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocovax vaccine (25 mcg, 50 mcg, and 75 mcg doses with 0.5 mg aluminium hydroxide adjuvant)
Number of subjects: 560
Study 35602004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 mg aluminium hydroxide adjuvant only)
Number of subjects: 560
Study 35602475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clindamycin and low dose TMP/SMX (CT group)
Number of subjects: 20
Study 35602475 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of TMP/SMX (T group)
Number of subjects: 20
Study 35602489 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120
Study 35602489 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 120
Study 35603037 — intervention group
Group type: EXPERIMENTAL
Intervention: CEASE intervention
Number of subjects: 11
Study 35603165 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFRvIII-directed CAR T cell therapy
Number of subjects: 0
Study 35603165 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35603278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispecific LV20.19 CAR T cell therapy
Number of subjects: 15
Study 35603289 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered elbow-wrist-hand orthosis using BCI
Number of subjects: 1
Study 35603289 — intervention group
Group type: COMPARATOR
Intervention: Myoelectric control
Number of subjects: 1
Study 35603289 — intervention group
Group type: COMPARATOR
Intervention: No device
Number of subjects: 1
Study 35603302 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory slow wave stimulation for two weeks
Number of subjects: 16
Study 35603302 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for two weeks
Number of subjects: 16
Study 35603455 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating microRNA profiles
Number of subjects: 200
Study 35603455 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma miRNA profiling using RT-qPCR
Number of subjects: 200
Study 35603455 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete pulmonary evaluation and chest computed tomography
Number of subjects: 200
Study 35603508 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miRNAs (miR-486-3p, miR-103a-3p, miR-106b-3p, miR-182-5p, miR-101-3p, miR-10a-5p, miR-125a-5p, miR-146b-5p, miR-26a-5p, miR-423-5p, miR-92b-3p)
Number of subjects: 5
Study 35603665 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status trajectories before and after hospitalization for heart failure
Number of subjects: 0
Study 35603667 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination medical therapy
Number of subjects: 0
Study 35603667 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35603905 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant/induction platinum-based combination chemotherapy (NAIC)
Number of subjects: 107
Study 35603905 — intervention group
Group type: COMPARATOR
Intervention: Combination immune checkpoint inhibition (cICI)
Number of subjects: 107
Study 35604152 — intervention group
Group type: COMPARATOR
Intervention: Placebo and psychologic intervention
Number of subjects: 261
Study 35604152 — intervention group
Group type: COMPARATOR
Intervention: Placebo and general education
Number of subjects: 261
Study 35604152 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and psychologic intervention
Number of subjects: 261
Study 35604152 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and general education
Number of subjects: 261
Study 35604203 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 83
Study 35604212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir coadministered with rifampicin
Number of subjects: 41
Study 35604212 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative dolutegravir dosing regimens
Number of subjects: 41
Study 35604343 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601/MLC901 for 6 months in addition to standard care and rehabilitation
Number of subjects: 30
Study 35604343 — intervention group
Group type: COMPARATOR
Intervention: Standard care and rehabilitation
Number of subjects: 30
Study 35604701 — intervention group
Group type: EXPERIMENTAL
Intervention: Struggling profile (n = 83; 45%)
Number of subjects: 186
Study 35604701 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping profile (n = 41; 22%)
Number of subjects: 186
Study 35604701 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping but concerned profile (n = 62; 33%)
Number of subjects: 186
Study 35604723 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth mental health screening using PHQ-9 and GAD-7
Number of subjects: 0
Study 35604754 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive travel health education
Number of subjects: 152
Study 35604754 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention (Control)
Number of subjects: 152
Study 35604758 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF)
Number of subjects: 791
Study 35604758 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Sodium Fluoride (NaF) varnish
Number of subjects: 791
Study 35604758 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (tonic water)
Number of subjects: 791
Study 35604806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 231
Study 35604806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Azithromycin
Number of subjects: 231
Study 35604806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 35605011 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma antibodies from SFV-infected individuals
Number of subjects: 29
Study 35605011 — intervention group
Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 29
Study 35605051 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing while expressing human milk
Number of subjects: 0
Study 35605184 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19.22.BBζ
Number of subjects: 20
Study 35605238 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cohort (n=189)
Number of subjects: 309
Study 35605238 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=120)
Number of subjects: 309
Study 35605238 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cohort (unvaccinated)
Number of subjects: 309
Study 35605238 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cohort (vaccinated)
Number of subjects: 309
Study 35605238 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cohort with PASC
Number of subjects: 309